It is well recognized that cAMP has important and multiple regulatory roles in sperm development. It also is crucial for the acquisition of sperm motility and competence in fertilization. Despite this knowledge, relatively little progress has been made in translating this understanding into clinical agents that might target cAMP for the development of contraceptive or fertility agents. Several reasons for this are apparent. Perhaps most importantly, it has proven difficult to identify targets that are relatively specific to the testis that might be expected to alter cyclic nucleotide metabolism or function selectively in this tissue. The fact that this second messenger system is ubiquitously used to regulate many systems in the body has proven a hindrance. Recently, two major advances have encouraged us to re-explore this option. First, a bicarbonate sensitive, """"""""sperm specific"""""""" adenylyl cyclase has been identified and characterized. This may provide the opportunity to develop both agonists and antagonists that will target sperm with relatively high selectivity. The second advance, which is the focus of this application, relates to the other side of the cyclic AMP equation, the cyclic nucleotide phosphodiesterases (PDEs) that degrade cAMP. Recently, we have identified three new phosphodiesterases that will hydrolyze cAMP, PDE8, PDE10, and PDE11, by using bioinformatic techniques. Two of these new ones, PDE8 and PDE11 are highly expressed in the testis and at least one of them, PDE8A, is expressed in developing sperm. In addition, earlier data show that other isozymes of PDE including several PDE1s, and PDE4s are also present in the testis. It seems likely that by pharmacological manipulation of one or more of the PDEs expressed in testis, perhaps along with the sperm specific adenylyl cyclase inhibitors or activators, that selective alteration in sperm function can be achieved. This hypothesis will first require a fuller understanding of the functions and roles of these enzymes in sperm development and function. This is the focus of this application.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54HD042454-01
Application #
6670087
Study Section
Special Emphasis Panel (ZHD1)
Project Start
2002-09-11
Project End
2007-02-28
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Rubinow, Katya B; Vaisar, Tomas; Chao, Jing H et al. (2018) Sex steroids mediate discrete effects on HDL cholesterol efflux capacity and particle concentration in healthy men. J Clin Lipidol 12:1072-1082
Haenisch, Michael; Treuting, Piper M; Brabb, Thea et al. (2018) Pharmacological inhibition of ALDH1A enzymes suppresses weight gain in a mouse model of diet-induced obesity. Obes Res Clin Pract 12:93-101
Berkseth, Kathryn E; Rubinow, Katya B; Melhorn, Susan J et al. (2018) Hypothalamic Gliosis by MRI and Visceral Fat Mass Negatively Correlate with Plasma Testosterone Concentrations in Healthy Men. Obesity (Silver Spring) 26:1898-1904
Rubinow, Katya B; Houston, Barbara; Wang, Shari et al. (2018) Androgen receptor deficiency in monocytes/macrophages does not alter adiposity or glucose homeostasis in male mice. Asian J Androl 20:276-283
Chen, Yan; Zhu, Jin-Yi; Hong, Kwon Ho et al. (2018) Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. ACS Chem Biol 13:582-590
Paik, Jisun; Treuting, Piper M; Haenisch, Michael et al. (2018) Can inhibition of retinoic acid biosynthesis function as a non-hormonal female contraceptive? Contraception :
Sharma, Manju; Braun, Robert E (2018) Cyclical expression of GDNF is required for spermatogonial stem cell homeostasis. Development 145:
Swerdloff, Ronald S; Dudley, Robert E; Page, Stephanie T et al. (2017) Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. Endocr Rev 38:220-254
Ayoub, R; Page, S T; Swerdloff, R S et al. (2017) Comparison of the single dose pharmacokinetics, pharmacodynamics, and safety of two novel oral formulations of dimethandrolone undecanoate (DMAU): a potential oral, male contraceptive. Andrology 5:278-285
Rubinow, Katya B; Chao, Jing H; Hagman, Derek et al. (2017) Circulating sex steroids coregulate adipose tissue immune cell populations in healthy men. Am J Physiol Endocrinol Metab 313:E528-E539

Showing the most recent 10 out of 129 publications